At mid-year, U.S. healthcare venture fundraising
reached $4.5 billion, and is on pace to closely match
the 2017 record of $9.1 billion. Great trends/insights from SVB.
The SVB State of the Markets report provides a quarterly update on the health and productivity of the global innovation economy. This quarter's report includes a special section on the booming Chinese tech industry.
Trends in Healthcare Investments and Exits 2018 - Mid-Year ReportSilicon Valley Bank
In our mid-year Healthcare Investments and Exits report, we analyzed the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
In our annual Healthcare Investments and Exits report, SVB analyzed the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
Trends in Healthcare Investments and Exits: Mid-Year 2017Silicon Valley Bank
In our mid-year 2017 report on healthcare investing, SVB analyzed the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
Investment and fundraising in the healthcare ecosystem saw a banner first half of 2017, driven in part by advancements in artificial intelligence and machine learning for healthcare applications and a surge in Series A investments, particularly in biopharma.
In its mid-year report on the healthcare industry, Silicon Valley Bank analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Report author Jonathan Norris also provides his view of what's on the horizon for the second half of 2016.
Silicon Valley Bank’s annual healthcare M&A report, Trends in Healthcare Investments and Exits, examines the merger and acquisition and IPO activity of private, venture-backed bio-pharma and medical device companies.
The study found that healthcare IPOs tripled in 2013, leading to record potential IPO/big exit returns of $12.5 billion.
For a detailed analysis access the report at: http://www.svb.com/healthcare-report_2014/.
**Report updated on 8/4/2014
In our annual report on the healthcare industry, Silicon Valley Bank analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
Silicon Valley Bank’s Trends in Healthcare Investments and Exits report analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Report author Jon Norris also gives his annual forecast of what’s likely to happen in 2016.
The SVB State of the Markets report provides a quarterly update on the health and productivity of the global innovation economy. This quarter's report includes a special section on the booming Chinese tech industry.
Trends in Healthcare Investments and Exits 2018 - Mid-Year ReportSilicon Valley Bank
In our mid-year Healthcare Investments and Exits report, we analyzed the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
In our annual Healthcare Investments and Exits report, SVB analyzed the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
Trends in Healthcare Investments and Exits: Mid-Year 2017Silicon Valley Bank
In our mid-year 2017 report on healthcare investing, SVB analyzed the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
Investment and fundraising in the healthcare ecosystem saw a banner first half of 2017, driven in part by advancements in artificial intelligence and machine learning for healthcare applications and a surge in Series A investments, particularly in biopharma.
In its mid-year report on the healthcare industry, Silicon Valley Bank analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Report author Jonathan Norris also provides his view of what's on the horizon for the second half of 2016.
Silicon Valley Bank’s annual healthcare M&A report, Trends in Healthcare Investments and Exits, examines the merger and acquisition and IPO activity of private, venture-backed bio-pharma and medical device companies.
The study found that healthcare IPOs tripled in 2013, leading to record potential IPO/big exit returns of $12.5 billion.
For a detailed analysis access the report at: http://www.svb.com/healthcare-report_2014/.
**Report updated on 8/4/2014
In our annual report on the healthcare industry, Silicon Valley Bank analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies.
Silicon Valley Bank’s Trends in Healthcare Investments and Exits report analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Report author Jon Norris also gives his annual forecast of what’s likely to happen in 2016.
What does 2017 hold for the Innovation Economy? In the latest State of the Markets report, SVB Analytics took a rear-view approach, identifying the factors that mattered most in 2016 and examining which trends and themes will play out in 2017.
New startup investment in the healthcare sector has undergone a gradual slowdown since Q4 2018. Explore more global trends in our report on the healthcare sector here http://bit.ly/hlt_sector
In a new report, SVB Analytics examines the challenges facing stakeholders in the U.S. healthcare system, the solutions made possible by technology advancements and opportunities for entrepreneurs and investors.
Learn more here: http://www.svb.com/Blogs/Alex_Lee/Digital_Health__Mapping_Digital_Health_Solutions/
Silicon Valley Bank's Life Science and Healthcare Startup Outlook Report examines how the industry's executives view 2017's opportunities and challenges. The report includes startups' thoughts on public policy issues as well as their expectations for fundraising and hiring.
What does the rest of 2016 hold for innovation companies? In a mid-year update on State of the Markets, the SVB Analytics team analyzed data from the first half of 2016 to identify key trends impacting SVB's clients.
The IPO Window Reopens:
We finally saw the IPO window crack open in Q3 2016, as proceeds from technology M&A are leaving investors flush with cash to reinvest and driving demand for IPOs and follow-on offerings.
In this third-quarter update on State of the Markets, my team analyzed investment and exit data to identify key trends impacting clients:
1. The number of IPOs exceeded private IPOs for the first time since Q2 2013, as crossover investors’ interest in large pre-IPO financings dropped off.
2. In the U.S., the pace of unicorn exits in Q3 exceeded new entrants.
3. After plummeting in the first half of 2016, values of publicly traded unicorns showed signs of recovery.
Learn more by reading the new State of the Markets report. As with any review of the markets, conditions can turn quickly. We are, however, confident that the fundamentals driving innovation will be strong through the end of 2016.
Silicon Valley Bank’s annual Startup Outlook survey provides insight into how startups in the US, UK and China are feeling about the year ahead. The 2016 report finds that while startups across the globe are eternally optimistic, they are preparing for a new reality.
Learn more about the Startup Outlook Report and view the UK and China reports at www.svb.com/IEO.
What does the rest of 2016 hold for the innovation economy? SVB Analytics' State of the Markets Report provides a summary of key market indicators impacting the innovation economy, including venture capital funding and valuation trends, crossover investor activity, and what’s ahead for the second half of 2016.
Arterial’s annual review of global healthcare is considered by many family offices, research analysts and wealth management groups to be the leading, authoritative report on the economic and political drivers and activity within the life science sector.
Arterial provide readers with an in-depth analysis of the past years’ investment trends within biotech, medtech and pharmaceuticals. The report analyses deal flow between private and institutional investors, identifies trends by sub sector, product and geographical / regional placement and concludes with our predictions for the year and decades ahead.
For the first time, SVB surveyed technology and life science entrepreneurs based in Canada. Like their counterparts in the US, UK and China, Canadian startups are optimistic about the year ahead even amid economic volatility. And while eager to hire and fundraise, they recognize the challenges they face. Most startups say Canadian government support of the innovation economy is having a positive impact. When it comes to gender parity, 60 percent of Canadian startups have at least one woman in an executive position. Looking ahead, we asked which technologies will have the most promise a decade from now: Canadian startups say AI and life science.
Start up health Insights Digital Health Funding Rankings 2016 Mid Year RankingDexter Wee
Source : Startuphealth.com
Digital Health Funding Ranking 2016 Mid Year Report
Seed and Series A deals are 65 % of the funding rounds.
7600 startups around the world.
The outlook for the Chinese tech sector is strong, with a large number of startups saying they expect more M&A opportunities. Access to talent and raising capital remain challenging. Compared to the US and UK, a higher percentage of Chinese startups have women in senior company roles and at least one woman on
the founding team.
For the 10th year, Silicon Valley Bank is proud to present
our Startup Outlook Report. The innovation economy has
expanded greatly in the US and abroad in the past decade,
and so has Startup Outlook. In our first report, we surveyed
300 people, most of them in California. The 2019 report
includes the perspectives of nearly 1,400 technology and
healthcare founders and executives primarily in major
innovation hubs across the US, the UK, China and, for the
first time, Canada.
Silicon Valley Bank’s annual Startup Outlook survey provides insight into how startups in the UK, US and China are feeling about the year ahead. The 2016 report finds that while startups across the globe are eternally optimistic, they are preparing for a new reality.
Learn more about the Startup Outlook Report and view the US and China reports at www.svb.com/IEO.
StartUp Health Insights Funding Report Q3 2017 YTDStartUp Health
Digital health funding broke all previous records in Q3, with 2017 YTD funding surpassing $9.0B. Assuming
momentum continues through Q4, we’ll finish 2017 well past $10B, a significant signal of support for
entrepreneurs working to achieve their Health Moonshots. Despite the headlines and uncertainty surrounding
healthcare reform, investment into digital health companies continues to accelerate.
TRENDS IN PRIVATE COMPANY FINANCING & EXITS IN OPHTHALMOLOGYHealthegy
Presentation by Silicon Valley Bank at OIS@ASRS 2016.
Participant:
Jonathan Norris, Managing Director - Silicon Valley Bank
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
2018 StartUp Health Insights Global Digital Health Funding Report 2018 MidyearStartUp Health
The first half of 2018 has brought an increase in deal volume and a total of $6.1B invested in digital health companies across the globe - showing a heightened confidence in the sector.
What does 2017 hold for the Innovation Economy? In the latest State of the Markets report, SVB Analytics took a rear-view approach, identifying the factors that mattered most in 2016 and examining which trends and themes will play out in 2017.
New startup investment in the healthcare sector has undergone a gradual slowdown since Q4 2018. Explore more global trends in our report on the healthcare sector here http://bit.ly/hlt_sector
In a new report, SVB Analytics examines the challenges facing stakeholders in the U.S. healthcare system, the solutions made possible by technology advancements and opportunities for entrepreneurs and investors.
Learn more here: http://www.svb.com/Blogs/Alex_Lee/Digital_Health__Mapping_Digital_Health_Solutions/
Silicon Valley Bank's Life Science and Healthcare Startup Outlook Report examines how the industry's executives view 2017's opportunities and challenges. The report includes startups' thoughts on public policy issues as well as their expectations for fundraising and hiring.
What does the rest of 2016 hold for innovation companies? In a mid-year update on State of the Markets, the SVB Analytics team analyzed data from the first half of 2016 to identify key trends impacting SVB's clients.
The IPO Window Reopens:
We finally saw the IPO window crack open in Q3 2016, as proceeds from technology M&A are leaving investors flush with cash to reinvest and driving demand for IPOs and follow-on offerings.
In this third-quarter update on State of the Markets, my team analyzed investment and exit data to identify key trends impacting clients:
1. The number of IPOs exceeded private IPOs for the first time since Q2 2013, as crossover investors’ interest in large pre-IPO financings dropped off.
2. In the U.S., the pace of unicorn exits in Q3 exceeded new entrants.
3. After plummeting in the first half of 2016, values of publicly traded unicorns showed signs of recovery.
Learn more by reading the new State of the Markets report. As with any review of the markets, conditions can turn quickly. We are, however, confident that the fundamentals driving innovation will be strong through the end of 2016.
Silicon Valley Bank’s annual Startup Outlook survey provides insight into how startups in the US, UK and China are feeling about the year ahead. The 2016 report finds that while startups across the globe are eternally optimistic, they are preparing for a new reality.
Learn more about the Startup Outlook Report and view the UK and China reports at www.svb.com/IEO.
What does the rest of 2016 hold for the innovation economy? SVB Analytics' State of the Markets Report provides a summary of key market indicators impacting the innovation economy, including venture capital funding and valuation trends, crossover investor activity, and what’s ahead for the second half of 2016.
Arterial’s annual review of global healthcare is considered by many family offices, research analysts and wealth management groups to be the leading, authoritative report on the economic and political drivers and activity within the life science sector.
Arterial provide readers with an in-depth analysis of the past years’ investment trends within biotech, medtech and pharmaceuticals. The report analyses deal flow between private and institutional investors, identifies trends by sub sector, product and geographical / regional placement and concludes with our predictions for the year and decades ahead.
For the first time, SVB surveyed technology and life science entrepreneurs based in Canada. Like their counterparts in the US, UK and China, Canadian startups are optimistic about the year ahead even amid economic volatility. And while eager to hire and fundraise, they recognize the challenges they face. Most startups say Canadian government support of the innovation economy is having a positive impact. When it comes to gender parity, 60 percent of Canadian startups have at least one woman in an executive position. Looking ahead, we asked which technologies will have the most promise a decade from now: Canadian startups say AI and life science.
Start up health Insights Digital Health Funding Rankings 2016 Mid Year RankingDexter Wee
Source : Startuphealth.com
Digital Health Funding Ranking 2016 Mid Year Report
Seed and Series A deals are 65 % of the funding rounds.
7600 startups around the world.
The outlook for the Chinese tech sector is strong, with a large number of startups saying they expect more M&A opportunities. Access to talent and raising capital remain challenging. Compared to the US and UK, a higher percentage of Chinese startups have women in senior company roles and at least one woman on
the founding team.
For the 10th year, Silicon Valley Bank is proud to present
our Startup Outlook Report. The innovation economy has
expanded greatly in the US and abroad in the past decade,
and so has Startup Outlook. In our first report, we surveyed
300 people, most of them in California. The 2019 report
includes the perspectives of nearly 1,400 technology and
healthcare founders and executives primarily in major
innovation hubs across the US, the UK, China and, for the
first time, Canada.
Silicon Valley Bank’s annual Startup Outlook survey provides insight into how startups in the UK, US and China are feeling about the year ahead. The 2016 report finds that while startups across the globe are eternally optimistic, they are preparing for a new reality.
Learn more about the Startup Outlook Report and view the US and China reports at www.svb.com/IEO.
StartUp Health Insights Funding Report Q3 2017 YTDStartUp Health
Digital health funding broke all previous records in Q3, with 2017 YTD funding surpassing $9.0B. Assuming
momentum continues through Q4, we’ll finish 2017 well past $10B, a significant signal of support for
entrepreneurs working to achieve their Health Moonshots. Despite the headlines and uncertainty surrounding
healthcare reform, investment into digital health companies continues to accelerate.
TRENDS IN PRIVATE COMPANY FINANCING & EXITS IN OPHTHALMOLOGYHealthegy
Presentation by Silicon Valley Bank at OIS@ASRS 2016.
Participant:
Jonathan Norris, Managing Director - Silicon Valley Bank
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
2018 StartUp Health Insights Global Digital Health Funding Report 2018 MidyearStartUp Health
The first half of 2018 has brought an increase in deal volume and a total of $6.1B invested in digital health companies across the globe - showing a heightened confidence in the sector.
2016 is on track to be the biggest year yet for digital health funding. Q3 was significant with almost $2.4B in deals, nearly half of which were international. We continue to see the market expand globally, with several large deals taking place both in the US and overseas.
StartUp Health Insights 2016 Midyear ReportStartUp Health
The digital health market broke historic records for midyear funding as investment reached $3.9B. Seed and Series A financing rounds are substantially equal in number, demonstrating a still thriving early-stage innovation landscape. Most funding dollars are being funneled to Series A rounds, creating opportunities for companies with validated solutions.
The State of the Venture Capital Industry is an annual report produced by TrueBridge Capital Partners highlighting the trends in venture fundraising, investing, valuations, exits, and performance.
All data sourced from Dow Jones VentureSource, Dow Jones LP Source, CB Insights, PitchBook, and Cambridge Associates.
StartUp Health Insights Global Digital Health Funding Report Q3 2018StartUp Health
A new benchmark has been set in the digital health market in Q3 2018, surpassing 2017 Q3 funding by almost $2B, hitting an all
time high Q3 mark of $11.1B. Record numbers of mid- and late-stage deals serve as a stabilizing force, creating market maturity
parallel to fund growth. International investments surge with Beijing as the home of five of the top ten international deals, and
European cities serving up an abundance of early-stage deals. With investors outpacing their 2017 totals, the digital health
market continues to be one of the fastest growing segments of the healthcare industry.
Arterial’s annual review of global healthcare is considered by many family offices, research analysts and wealth management groups to be the leading, authoritative report on the economic and political drivers and activity within the life science sector.
Arterial provide readers with an in-depth analysis of the past years’ investment trends within biotech, medtech and pharmaceuticals. The report analyses deal flow between private and institutional investors, identifies trends by sub sector, product and geographical / regional placement and concludes with our predictions for the year and decades ahead.
2017 StartUp Health Insights Year End ReportStartUp Health
As predicted, digital health investment reached new heights in 2017 with $11.5B in funding across 794 deals. Looking beyond the
numbers provides insight into a sector transitioning to a more mature phase. Deal activity at the early stage has fueled a startup
wave and a maturing market with more later-stage opportunities is attracting new investment globally. 2018 is poised to be a
dynamic year in terms of digital health funding activity, M&A and breakout successes, and experimentation paving the way for
new advancements.
StartUp Health Insights Global Digital Health Funding Report Q1 2018StartUp Health
2018 Q1 continued the wave of digital health investment activity - the most deal volume of any first quarter since we’ve been tracking data - totaling $2.8B of investment across 191 deals. In addition, we’re seeing more deal flow at every stage, across a spectrum of companies and technologies, from an increasing ecosystem of investors.
Asia HealthTech Investment Landscape 2017 Full Year reportGalen Growth
We are pleased to share the 2017 Full Year Asia HealthTech Investment Landscape report, a full update of our most popular report in 2017.
As we predicted last July, 2017 was a record-breaking year for HealthTech in Asia Pacific with funding exceeding the US$2.6B mark! Asia also saw a landmark of 230 deals executed in 2017, thus doubling 2016’s total.
Similar to Healthcare Investment and Exits Report - 2018 (20)
An exceedingly valuable template for developing startup presentations. This was created by a VC who interviewed multiple venture capitalists and sought advice on the best ways to "tell your story," communicate value, scarcity and risk-mitigation. An essential tool. Check it out. Mike www.inflectoinpointconsult.com
Leadership & Entrepreneurial Success require certain essential characteristics. These competencies of success are learnable and are needed both at work and in personal life.
From Bootstrapping to Crowdfunding, the financing of startup companies requires a range of considerations along with "funding creativity" and strong dose of persistence. Great value propositions have to find a way to get funded. Here's how.
Know how venture capitalists value your deal....understand how they are compensated...see what creates value and how investors assess your "risk factors."
A great slide show presentation that provides solid answers to many of these essential questions Check out mikeklein2010.wordpress.com
Essential elements that pitch decks must have in one for or another. Must add industry and domain elements, but these are a few critical elements. mikeklein2010.wordpress.com
Critical info on investment challenges and opportunities in medical technology investing. Sage advice from Silicon Valley Bank. www.mikeklein2010.wordpress.com
Assumptions of the workforce of the past 20 years do not apply as we march headlong towards 2020. This useful overview will help you prepare to "win the future."
The key do's and don't for startup financing. Avoid the painful mistakes that turn investors off. Find the hot buttons that attract investors. Medical Technology, in particular has certain "hot buttons" that must be address in preparing to present to investors.
More from Inflection Point Executive Coaching & Consulting for Med/Tech, BioPharma and Healthcare Services (13)
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
The global radiation oncology market size reached US$ 8.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/radiation-oncology-market
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...The Lifesciences Magazine
Cold Sores, medically known as herpes labialis, are caused by the herpes simplex virus (HSV). HSV-1 is primarily responsible for cold sores, although HSV-2 can also contribute in some cases.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
Tips for Pet Care in winters How to take care of pets.
Healthcare Investment and Exits Report - 2018
1. Trends in Healthcare
Investments and
Exits 2018
Innovation Wave Drives Robust Activity
MID-YEAR REPORT 2018
Follow @SVB_Financial Engage #SVBHealthcare
2. Table of Contents
Trends in Healthcare Investments and Exits Mid-Year 2018 2
Mid-Year 2018 Key Highlights 3
Healthcare Investments and Fundraising 5
SVB Deep Dive: Tools Driving Synthetic Biology in Life Science 18
Healthcare Exits and IPOs 20
Biopharma Unicorns: 2013 – 2018 21
Second Half of 2018 Outlook 29
Glossary 30
About the Authors 31
4. Mid-Year 2018 Highlights: Exits
Biopharma IPOs Are Poised to Blow Past 2017 Numbers
Trends in Healthcare Investments and Exits Mid-Year 2018 4
• 75 VC-backedbiopharmaunicornshavereached
valuationsof$1 billionorhighersince2013– either
throughacquisition orin thepublicmarkets.This year
is shapinguptobeanotherstrongyear. These
biopharmaexitsarecreatingthemomentumfor
strongfundraisingand investment.
• In 1H2018, 30biopharmacompanieswentpublic–
comparedto31 IPOs forallof2017.
• BiopharmaM&Ais slowing,as largerroundsand
highervaluationsmakeearly-stageM&Aless
appealing.
• Instead, companieslookingtogopublicare
replenishingthebiopharmaIPO queue.This is fueled
by largepre-moneyIPO valuationsdrivenby
continuedtopcrossoverinvestoractivity.
• DeviceM&Ais stable,buttheIPO marketis favoring
neuro-focusedcompanies,withthreeIPOs in 1H
2018.
• PMA/DeNovopathwaycompaniescontinueto
achievebetterM&Avalues,highermultiplesand
fastertimestoexitthan510(k) companies.
• However,overthelast twoyears, 510(k) device
valuesand multipleshaveincreased.
• Dx/ToolsM&Aactivity is increasing,butthesedeals
havelowerupfrontvaluesand longertimesto exit.
• Thereare manylater-stageDx/Toolscompaniesthat
areshapingupas acquisition candidates, with25
still-privatecompaniesvaluedat $150 millionor
higher.
5. 5
Healthcare Investments and Fundraising:
Biopharma Advancements Drive
Investor Activity
Trends in Healthcare Investments and Exits Mid-Year 2018
6. Trends in Healthcare Investments and Exits Mid-Year 2018 6
U.S. HC Venture Fundraising Stays on Torrid Pace
U.S. Healthcare Venture Fundraising*, 2009 – 2018
$5.2
$1.8
$3.7 $3.6
$3.9
$6.1
$7.5
$7.2
$9.1
$4.5
2009 2010 2011 2012 2013 2014 2015 2016 2017 1H 2018
Fundraisingisonpacetomatchthe2017
totalof$9.1B–countertoourearly2018
predictionthattheannualtotalwould
decline.Aconfluenceofeventsisdriving
investmentandfundraisingtonewlevels.
Rapidtechnologicaladvances,leadingto
clinicalbreakthroughs,arebenefiting
patientsandinvestorsalike.Inthis
environment,quickexitsareunderpinningan
explosionof activity,particularlyin
biopharma,attractingnewpoolsofcapital
andgiantinvestmentsbytraditionalandnon-
traditionalinvestors,includingtechinvestors.
Withtheentryof artificialintelligence(AI)
andmachinelearning(ML),thesetech
investorsseehugeopportunitiesindrug
developmentandthetoolsrequiredtohelp
identifycuresfor arangeofdiseases.
ThebiopharmaIPOwindowisrewarding
investorswithquickvaluationstep-ups
(manycompanieshadIPOswithintwoto
threeyearsofSeriesA).Thispathtoliquidity
istranslatingintorenewedexcitementby
limitedpartnerswhoare eagertokeepthe
investmentcyclegoingbysupportinglarger
venturefundraisesatafasterpace.
*SVB calculates only the dollars allocated to healthcare by U.S. venture funds orfunds investing
primarily in the U.S.
Source:PitchBook and SVB proprietary data.
HC VC $ Fundraised
($ BILLIONS)
7. 36
18
14
16
5
32
19
12
12
9
19
17
11
6
3
Oncology
Platform
Orphan/Rare
Disease
Neuro
Anti-
Infective 2016 2017 1H 2018
2016* 2017* 1H 2018
# of Investments 122 128 77
Total Series A Funding ($M) $2,299 $2,259 $2,632
Corporate Investments (%) 26% 31% 16%
Trends in Healthcare Investments and Exits Mid-Year 2018 7
Biopharma Series A Deals Set Blazing Pace
U.S. Series A Biopharma Investments, 2016 – 1H 2018
$1,395M
$987M
$650M
$281M
$2,362M
*2016 &2017 numbers amended based on PitchBook financing updates. Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
2017 Median Series A Funding by Quarter ($M)
75th
Quartile
25th
Quartile
2018 Median Series A Funding by Quarter ($M)
$19.1
$6.9 $5.9 $11.0
$-
$10.0
$20.0
$30.0
$40.0
$50.0
$60.0
2017Q1 2017Q2 2017Q3 2017Q4
$8.0
$32.5
$-
$10.0
$20.0
$30.0
$40.0
$50.0
$60.0
2018Q1 2018Q2
By mid-year, biopharma Series A investments reached $2.6B, already surpassing the full-year 2017 total.
The activity was punctuated by a total of $1.8B invested in 15 big-money deals. Four deals each raised $250M+ (Allogene, Harmony, Viela and
Cellularity), and an additional 11 deals each raised $50M+.
Series A investment is on pace to reach 150 deals in 2018. Tech, angel and incubator/accelerator investors drove Q1 deal-making. Large
venture healthcare syndicates (with corporates) led Q2 activity in fewer deals, driving up the Q2 2018 median deal value to more than $30M.
Oncology
Platform
Orphan/
Rare Disease
Neuro
Anti-
Infective
Series A Deals
Series A by Indication
8. Trends in Healthcare Investments and Exits Mid-Year 2018 8
Venture and Crossovers Lead Biopharma Activity
Most Active New Investors* in Biopharma, 2017 – 1H 2018
*Most ActiveNew Investors in biopharma defined as Top 60 venture and corporate investors based on new investments in 2016–2017.
Financing data through 6/15/18. Platform companies have technologies with multiple ornon specified indications.
Source:PitchBook and SVB proprietary data.
26
20
17
15
13
12
11
10
9
8
7
New investors joining the most
active list include 5AM, 6
Dimensions, HBM, Third Rock,
Versant and crossovers RA
Capital and Rock Springs.
By indication, the most active
investors in platform
companies were Arch, Orbimed
and Third Rock (4+ deals
each), in oncology were 6
Dimensions, Celgene, GV,
Orbimed, Osage, Versant and
Vivo (4+ deals each) and in
orphan/rare were 5AM,
Orbimed and RA Capital (3+
deals each).
# OF DEALS
Corporate Investor
9. 44
30
18
13
9
5
8
7
3
3
3
3
5
2
4
1
1
6
1
2
Oncology
Platform
Orphan/Rare Disease
Neuro
Anti-Infective
Auto-Immune
Metabolic
Early Stage Late Stage Undesignated
Trends in Healthcare Investments and Exits Mid-Year 2018 9
Oncology and Platform Deals Capture Most Interest
Most Active New Investments* in Biopharma by Indication, 2017 – 1H 2018
$2,486M
$907M
$2,276M
$999M
$639M
$648M
$286M
Underscoring the recent influx of capital over the past two years from the most active investors, every top indication in 1H 2018 other than
oncology has already surpassed investment levels for full-year 2016.
Waves of new biopharma investment are pushing funding for platform companies to levels similar to oncology and driving a comeback for
orphan/rare drugs.
*Most ActiveNew Investments in biopharma defined as Top 60 venture and corporate investors based on new investments in 2016–2017.
Platform companies have technologies with multiple ornon specified indications. Early Stage defined as Series A &B; LateStage defined as Series Cand later.
Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
# DEALS | $ MILLIONS
Platform
Orphan/Rare
Ophthalmology
Auto-immune
Trends:
10. Trends in Healthcare Investments and Exits Mid-Year 2018 10
Robust IPOs Lead to Soaring Private Valuations
Series A/B Deals, Size and Valuation by Most Active Investors*, 2013 – 1H 2018
14.3
25.522.8
28.5
22.0
44.0
28.7
42.2
28.6
44.946.0
58.0
0.0
20.0
40.0
60.0
Series A Series B
2013 2014 2015 2016 2017 1H 2018
Median Round Size by Series
Median 2-Year Series A to Series B Step-ups
0.8
3.2
2.3
0.0
1.0
2.0
3.0
4.0
Series A - Series B
2014-2016 2015-2017 2016-1H 2018
Roundsizesbythemost
activeinvestorshave
explodedin1H2018.
Thishasbeenledbytop
15crossoverinvestors,
whohaveshiftedfrom
laterstage(SeriesC/D)to
earlierstage(SeriesA/B)
withtheexpectationof
quickIPOs.For IPOs
involvingtop15
crossoverinvestors,it
tookamedian7.5months
fromtheirlastprivate
financingtogopublic.
Higherpre-moneyIPO
valuationsareleadingto
largerstep-upsfrom
SeriesA toB,allowing
companiestoraisemore
moneyandincrease
valuations.SeriesA toB
valuationstep-upshave
soaredto3.2xin2017
and2.3xin1H2018.
*Most ActiveBiopharma Investors by Indication defined as Top 42 venture and corporate investors calculated as new (first-time) investments into companies.
Crossover investors defined as public-minded investors who opportunistically invest in private deals. Numbers denote median values.
Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
11. 4
6
5
5
3
7
11
8
7
3
4
7
2
2
4
5
2
Non-Invasive
Monitoring
Orthopedic
Neuro
Cardiovascular
Imaging
Ophthalmology
2016
2017
1H 2018
2016* 2017* 1H 2018
# of Investments 60 59 37
Total Series A Funding ($M) $284 $333 $232
Corporate Investments (%) 12% 21% 8%
$120M
$78M
$86M
$79M
$45M
Trends in Healthcare Investments and Exits Mid-Year 2018 11
Non-Invasive Monitoring Drives Device Series A
U.S. Series A Device Investments, 2016 – 1H 2018
HC Insurers/Providers
Medical Device
Digital/Wellness/NIM
$29M
Biopharma
*2016 &2017 numbers amended based on PitchBook financing updates. Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
Device Series A in 1H 2018 is slightly ahead of the 2017 pace, measured by deals and dollars.
Hospital digitization technologies offered by non-invasive monitoring and imaging companies are driving 1H 2018 Series A activity. However, neuro-
focused companies lagged.
Since 2017, health insurers/providers and Chinese companies have led corporate investments in Series A device. J&J is the only traditional corporate
to do a Series A deal since 2017, completing 3 early-stage investments.
Series A Deals
Series A by Indication
Series A Corporate Investors: 2017 – 1H 2018
12. Trends in Healthcare Investments and Exits Mid-Year 2018 12
Traditional Venture Investors Support Device
Most Active New Investors* in Device 2017 – 1H 2018
7
5
4
3
# OF DEALS
New Enterprise Associates and Aperture Venture Partners join the most active new investor list.
Early-stage groups like Keiretsu and FundRx are aggregating angel interest when approaching device investments.
Corporate investor activity has declined. The most active corporate investors, J&J and Boston Scientific, are also major acquirers.
*Most ActiveNew Investors in medical devicedefined as Top 21investors based on new investments in 2016–2017.
Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
Corporate Investor
13. 5
4
5
3
1
4
2
1
1
4
3
4
2
2
1
1
2
4
1
1
Cardiovascular
Neuro
Orthopedic
Surgical
Metabolic
Vascular
Non-Invasive
Monitoring
ENT
Aesthetics/
Dermatology
Early Stage Late Stage Undesignated
Trends in Healthcare Investments and Exits Mid-Year 2018 13
Device Investing Stays Consistent
Most Active Device Investors by Indication*, 2017 – 1H 2018
$338M
$182M
$149M
$219M
$84M
$100M
$73M
$76M
# DEALS | $ MILLIONS
$200M Orthopedic
NIM
Drug Delivery
Trends:
*Most ActiveDevice Investors defined as Top 35 venture and corporate investors calculated as new investments into companies in 2016 –2017.
Early Stage defined as Series A & B; Late Stage defined as Series Cand later.
Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
While active investor activity by indication is closely mirroring previous years, non-invasive monitoring (which has received a lot of early
stage Series A interest) and drug delivery investment have not scaled as expected.
Three neuro IPOs and a pair of uro/gyn M&A deals may spur additional interest in those areas.
Cardiovascular
Neuro
Metabolic
Surgical
ENT
Orthopedic
Vascular
Non-invasive
Monitoring
Aesthetics/
Dermatology Logos represent $25M+ financings
14. 1.7
2.2
0.6
1.7
0.8
1.1
1.4
1.2 1.2
2.0
1.4
0.7
0.0
1.0
2.0
3.0
Series A - Series B Series B - Series C Series C - Series D
2013-2015 2014-2016 2015-2017 2016-1H 2018
4.3
6.5
10.0 11.0
5.0
10.3
8.0
15.0
6.3
8.2
15.3
22.2
6.6
10.0
15.0
20.0
5.7
8.0
17.9
20.0
8.3
14.4
27.0
13.0
0.0
10.0
20.0
30.0
Series A Series B Series C Series D
2013 2014 2015 2016 2017 1H 2018
Median Round Size ($M) by Series 2013 – 1H 2018
Median 2-Year Series/Series Step-ups 2013 – 1H 2018
Trends in Healthcare Investments and Exits Mid-Year 2018 14
Device Round Sizes Increase as Later-Round Valuations Drop
Median Round Size and Valuations (Pre/Post) by Series, 2013 – 1H 2018
Device round sizes have increased for Series A-C, up 2x in 1H 2018 over 2013.
Series A to B valuation step-ups have recently reached as high as 2x. But Series C to D valuations are flat or down rounds, as later-stage investors
may be bargain hunting with limited capital. This hampers returns for early-stage investors.
Medical device companies funded between 2013and 1H2018.
Source:PitchBook and SVB proprietary data as of 5/31/18
15. 26
20
8
42
22
9
16
7
4
R&D Tool
Dx Test
Dx Analytics
2016 2017 2018
2016* 2017* 1H 2018
# of Investments 54 73 27
Total Series A Funding ($M) $481 $548 $224
Corporate Investments (%) 21% 20% 17%
Trends in Healthcare Investments and Exits Mid-Year 2018 15
Dx/Tools Series A Activity Declines from Record 2017
U.S. Series A Dx/Tools Investments, 2016 – 1H 2018
$678M
$374M
$201M
Streamlined Dx Tests
Neuro-Focused
3D Tissue Bioprinter
Oncology-Focused
NGS-Enabling Tools
$5M+ Investments in 1H 2018
Dx/Tools Series A funding and deals decreased in 1H 2018 after a strong 2017.
Dx Analytics companies had fewer deals but raised larger rounds in 1H 2018 with a median deal size of $18M.
AI/ML dominated $10M+ Series A deals in 2017 (7/13), but only had one deal at $5M+ (PAIGE.AI) in 1H 2018.
*2016 &2017 numbers amended based on PitchBook financing updates.
Dx Tests are yes/no tests. Dx Analytics provide more information for diagnosis/treatment. R&D tools advance researchers’ capabilities.
Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
Series A Deals
Series A by Subsector 2016 – 1H 2018
16. 8
6
5
4
Corporate Investor
Trends in Healthcare Investments and Exits Mid-Year 2018 16
New Tech Investors Join Most Active Dx/Tools List
Most Active New Investors* in Dx/Tools, 2017 – 1H 2018
# OF DEALS
The list of tech-focused investors active in Dx/Tools is impressive: Andreessen Horowitz and Alumni Ventures Group in 1H 2018 joined return
investors AME Cloud Ventures, Data Collective, Google Ventures, Khosla Ventures and Tencent. We anticipate new tech-focused venture and
corporate investors to become more active as opportunities to leverage software-based big data solutions emerge.
*Most ActiveDx/Tools Investors calculated based onnew (first-time) investments into companies from
2017 to 1H2018. Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
17. Dx Test
Dx
Analytics
R&D Tool
Trends in Healthcare Investments and Exits Mid-Year 2018 17
Dx/Tools Sector Dips in 1H 2018 but R&D Tools Surge
Most Active Dx/Tools Investors* by Subsector, 2017 – 1H 2018
$1,889M
$1,146M
$1,443M
16 ($1,837M) 5
Dx/Tools saw $801M in investments by the most active investors in 1H 2018, compared to $2.8B invested in full-year 2017.
Dx Analytics funding dropped to $322M with a focus on early-stage (seed and Series A/B). Dx Tests financing fell off the cliff from 2017,
with just $52M in investments in 1H 2018; four big-money deals (including GRAIL and Guardant) pushed up investment totals in 2017.
On the bright side, R&D Tools soared to 20 deals, with investments totaling $427M. That represents more than half of 1H 2018 Dx/Tools
funding. 34% of R&D Tools investments were in tools that accelerate synthetic biology research, as detailed in the following slides.
Logos represent $25M+ financings
# DEALS | $ MILLIONS
Dx Tests
Dx
Analytics
R&D Tools
*Most ActiveDx/Tools Investors calculated based onnew investments into companies from 2017 to 1H2018.
Dx Tests are yes/no tests. Dx Analytics provide more information for diagnosis/treatment. R&D tools advance researchers’ capabilities.
Financing data through 6/15/18.
Source:PitchBook and SVB proprietary data.
2017 1H 2018
$52M
28 ($1,121M) 8 ($322M)
33 ($719M) 20 ($427M)
18. $0
$50
$100
$150
$200
$250
$300
$350
$400
$450
2015 2016 2017 2018
Design Editing Synthesis Engineering
Trends in Healthcare Investments and Exits Mid-Year 2018 18
SVB Deep Dive: New Tools Accelerating Synthetic
Biology in Life Sciences
Investment by Synthetic Biology Subsector
Computational design technologies provide data-backed suggestions for optimizing experiments and new molecules. CRISPR editing technologies simplify genemodifications.
DNA/RNA synthesis technologies create DNA/RNA. Organism engineering technologies introduce DNA/RNA orediting tools into cells ororganisms.
Financing data through 6/15/18.
Source:PitchBook, press releases and SVB proprietary data.
Computational Design
Organism Engineering
CRISPR
Editing
DNA/RNA
Synthesis
Large-scale synthetic biology is being
simplified by innovations like
CRISPR gene editing and machine
learning. A new flood of therapeutics
investment built around genome
engineering is leveraging these
groundbreaking technologies.
This analysis focuses on companies
making these tools that do not have a
clinical or agricultural/industrial
product pipeline.
Buoyed by $100M+ investments in
Zymergen, Twist Bioscience and
Gingko Bioworks, sector financing
has grown since 2015. While most
investment has been in organism
engineering, nucleic acid synthesis
has dominated 1H 2018.
DEAL SIZE | $ MILLIONS | 2015 – 1H 2018
19. Trends in Healthcare Investments and Exits Mid-Year 2018 19
SVB Deep Dive: Innovation in DNA/RNA Synthesis
Companies with Venture-Backed Deals, Total Raised to Date
HARDWARE ADVANCES BIOCHEMICAL ADVANCES
>$50M
High-Throughput,Silicon
Platformthat Reducesthe
Needed Volumesfor DNA
SynthesisReactions
Pairs High-Throughput
SiliconPlatformwith Error
Detectionand Annealing
for CheckingDNA Quality
Developinga Microfluidic,
AutomatedSystemto Bring
DNA Synthesisinto the Lab
UtilizesReusable
EnzymesfromDead
Cellsto Produce RNA
Template-FreeDNA
Synthesisthrough
ProprietaryEnzymes
Template-FreeDNA
Synthesisthrough
ProprietaryEnzymes
DNA/RNA synthesis technologies create DNA/RNA.
Financing data through 6/15/18.
Source:PitchBook, press releases and SVB proprietary data.
TOTALRAISEDTODATE
Semiconductor-based technology popularized by Twist Bioscience has now made high-throughput DNA/RNA synthesis possible.
Evonetix builds upon this platform by integrating multiple reaction sites on the chip surface to error-check the synthesized DNA,
and Synthomics aims to bring synthesis capabilities into labs by automating the entire process in a microfluidics-based device.
Greenlight Biosciences, DNA Script and Molecular Assemblies utilize biocompatible enzymes to avoid error-prone synthesis steps.
Integrating this enzymatic approach into recent hardware advances is ushering in a new era of synthetic biology research.
$5–50M<$5M
20. 20
Healthcare Exits and IPOs:
Biopharma IPOs Surge
while M&A Slows
Trends in Healthcare Investments and Exits Mid-Year 2018
21. Trends in Healthcare Investments and Exits Mid-Year 2018 21
Investors Find Blessing in 75 Biopharma Unicorns*
VC-backed Biopharma $B+ M&A, Current Public Values, 2013 – 1H 2018
Public Unicorns by IPO Vintage: 46 Deals
$B+ M&A Unicorns by Year: 19 Private/10 Public
*Unicorn defined as venture-backed company since 2013that achieved an M&A with $B+ total deal
value oris a public company (IPO since 2013) valued at $B+ as of 6/15/18.
Source:PitchBook, press releases and SVB proprietary data.
The hot biopharma sector has created a blessing of 75 unicorns between 2013 and 1H 2018. Half of private M&A unicorns were pre-clinical or Phase
I (10/19), while all of the public M&A unicorns were Phase III (9) or commercial (1).
Not all biopharma companies are build-to-sell. In fact, 61% of unicorns (46/75) have gone public and become stand-alone high-value companies. Of
the 46 public unicorns, top 15 crossover investors participated in 31 of these deals prior to the IPO.
2013 2014 2015 2016 2017 2018
2013 2014 2015 2016 2017
Private M&A Public M&A
22. 33
67
42
28
31
30
12
14
22
20
14
5
2013
2014
2015
2016
2017
1H 2018
IPO M&A
23
8 10 5 4
55
29 25
19 16
Oncology Orphan/Rare Disease Neuro Anti-Infective Platform
M&A IPO
$-
$5
$10
$15
$20
$25
$30
2013 2014 2015 2016 2017 1H 2018
M&A Upfront M&A Milestones Pre-Money IPO
Trends in Healthcare Investments and Exits Mid-Year 2018 22
Biopharma M&A Slows as IPOs Heat Up
VC-backed Biopharma Big Exits & IPOs, 2013 – 1H 2018
Source:PitchBook, press releases and SVB proprietary data.
$17.7B
$21.3B
$26.9B $26.5B
$18.7B $20.0B
Exit Values by Year
$ BILLIONS
Top Exits by Indication
2013 – 1H 2018
As is typical in a hot IPO market,M&A activityslowed significantlyin 1H
2018. By mid-year,30 biopharma IPOs had priced– comparedto 31 for all of
2017.
The biopharma IPO queueis substantial,and 2H 2018 activity will likely
push the full year total to between40 and 45 – far surpassing our early 2018
predictionof 28 to 32.
Thoughthe numberof deals declined,total M&A deal valuein 1H 2018
alreadyhas blownpast the total for full-year2017. However,hugemilestones
drive thesedeals: 3 involvepotentialearn-outsof $900M or higher.
Oncologyled the 1H 2018 M&A/IPO exit pack (10), followedby platform(7),
orphan/rare(4) and aesthetics/dermatology(4). Aesthetics/dermatologyis a
surprise becauseof its relativelysmall investmentlevels.
# of Exits by Year
23. Trends in Healthcare Investments and Exits Mid-Year 2018 23
Smaller Early-Stage Deals Dominate Biopharma M&A
VC-backed Biopharma Big Exit M&A by Stage* 2013 – 1H 2018
*Stage defined as last completed clinical trial in most advanced asset.
Source:PitchBook, press releases and SVB proprietary data.
1
5
7
2
5
1
2
3
4
8 2
3
4
4
10
9
5
2
1 1
1
3
1
1
1
2013 2014 2015 2016 2017 1H 2018
While overall M&A activity is down,
1H 2018 saw 4 early-stage exits –
which signals that pre-clinical/Phase
I deals may hit the typical annual
total of 7 to 11 exits.
The 1H 2018 median milestone earn-
out of $900M is nearly double the
median from 2015 to 2017.
Smaller early-stage deals, with
median investment of $17M, are
providing quick times to exit of 3.1
years. They are also yielding a 7x
median upfront multiple on invested
capital, making the deals attractive
to investors.
To exit at an early stage, companies
typically need to show a minimum 3x
to investors. However, early-stage
investment rounds are shifting to
$50M and higher, and with the
median M&A upfront value at $123M,
a 3x return is out of reach. Instead,
these companies are heading to the
public markets with pre-money IPO
valuations far exceeding the private
upfront M&A value, providing a hefty
step-up from the last private round
and generating large IPO proceeds to
continue asset development.
Median Upfront($M) 213 225 200 200 171 123
Median Total Deal($M) 457 413 570 600 461 1040
Median Years to Exit 5.6 4.0 4.2 5.9 3.5 3.1
Phase III
Phase II
Phase I
Pre-Clinical
Commercial
$7.0B
$8.0B
$16.6B
$21.2B
$8.9B
$9.9B
# of Big Exits
24. $182
$129
$193
$140
$294
$327
0
50
100
150
200
250
300
350
400
450
500
2013 2014 2015 2016 2017 2018
$71 $61 $71
$53
$85
$100
0
20
40
60
80
100
120
140
2013 2014 2015 2016 2017 2018
IPO Pre-Money Value*
$ MILLIONS
Trends in Healthcare Investments and Exits Mid-Year 2018 24
Biopharma Pre-Money Values Drive Hot IPO Scene
VC-backed IPOs by Pre-Money Valuation and Dollars Raised, 2013 – 1H 2018
Source:PitchBook, press releases and SVB proprietary data.
*Pre-money IPO valuation divided by venture capital invested. Private valuations sourced through PitchBook.
2013 2014 2015 2016 2017 1H 2018
IPOs Raised $100M+ 8 12 13 1 12 17
% of IPOs Raised $100M+ 24% 18% 31% 4% 39% 57%
IPO Proceeds
$ MILLIONS
75th
Quartile
25th
Quartile
IPO Median Pre-Money IPO Median Dollars Raised
Half of H1 2018 IPOs raised at least $100M, spurred on by pre-money IPO valuations hitting cycle-highs. The median step-up from
last round private money to pre-money IPO was 1.2x. About half of the IPOs were pre-clinical/Phase I (14/30).
Top 15 crossover investors remain major players, as an impressive 21 of 30 IPOs included at least one top 15 crossover investor in
the private syndicate. These IPOs had a higher median pre-money value ($341M) and better step-up from last round private money
(1.3x). Historically, these IPOs perform better in the public markets.
1H 1H
25. 21
12 11
5
8
1
4
4
6
3
Cardiovascular Vascular Access Surgical Neuro Ophthalmology
M&A IPO
$-
$1
$2
$3
$4
$5
$6
$7
$8
2013 2014 2015 2016 2017 1H 2018
M&A Upfront M&A Milestones Pre-Money IPO
2
10
11
3
3
3
12
18
19
13
14
6
2013
2014
2015
2016
2017
1H 2018
IPO M&A
Trends in Healthcare Investments and Exits Mid-Year 2018 25
Device M&A Activity Stable but IPO Window Cracks Open
VC-backed Device Big Exits & IPOs, 2013 – 2017
Exit Values by Year
$ BILLIONS
Top Exits by Indication
2013 – 1H 2018
Source:PitchBook, press releases and SVB proprietary data.
$2.8B
$6.4B
$7.6B
$4.9B $4.9B
$2.6B
The slow start to the year is typical for device, and activity
should increase in 2H 2018. J&J and Boston Scientific
continue acquiring venture-backed companies, but
Medtronic and Abbott remain quiet after huge public
acquisitions in 2015 and 2017. Further consolidation among
large device companies could hurt M&A exits.
The three device IPOs in 1H 2018 equal full-year 2017
activity. Neuro-focused IPOs by Inspire Medical Systems,
electroCore and Neuronetics have performed well and could
lead to a few more IPOs by revenue-generating device
companies in 2H 2018.
# of Exits by Year
26. 1 1
4
2
3
1
3
1
5
4
3
8
15
10
7
8
5
0
2
4
6
8
10
12
14
16
18
20
2013 2014 2015 2016 2017 1H 2018
Trends in Healthcare Investments and Exits Mid-Year 2018 26
Device M&A Upfront Deal Values Dip
VC-backed Device Big Exit M&A by Stage 2013 – 1H 2018
By indication, 1H 2018 M&A
exits were cardiovascular (2),
uro/gyn (2), orthopedic (1) and
non-invasive monitoring (1).
Cardiovascular has remained
strong for the last 5 years.
Building on a two-year trend, 4
of 6 device deals had milestone
earn-outs.
The sole PMA/De Novo
acquisition was for a non-
approved device and the four
510(k) acquisitions had FDA
approvals.
Median Upfront($M) 127 180 125 120 131 113
Median Total Deal($M) 175 185 141 380 283 263
Median Years to Exit 6.6 6.9 7.0 8.1 7.7 13.4
U.S. Commercial
CE Mark Only
Non-approved
$2.3B
$4.3B
$3.7B
$4.4B
$4.7B
$1.6B
Source:PitchBook, press releases and SVB proprietary data.
# of Big Exits
27. 510(k) Big Exits (29 Deals)
2015 – 1H 2018
2015 – 2016
(18 Deals)
2017 – 1H 2018
(11 Deals)
Median Upfront Value ($M) $105M $125M
Median Upfront Deal Multiple 2.2X 3.5X
Median Total Deal Value ($M) $110M $250M
Median Total Deal Multiple 2.6X 5.7X
Trends in Healthcare Investments and Exits Mid-Year 2018 27
PMA/De Novo Deals Exit Pre-FDA Approval
VC-backed Device M&A by Pathway, 2015 – 1H 2018
2015 – 1H 2018 Stage at Exit
Median
Invested
($M)
Median
Upfront
($M)
Median
Upfront
Multiple
Median
Total Deal
($M)
Median
Total Deal
Multiple
Median
Time to
Exit
(Years)
510(k)M&As
29 Exits $46 $110 3.1x $135 3.6x 9.1
PMA/DeNovo
510(k)M&As
22 Exits
$45 $225 4.0x $353 6.8x 5.5
BiopharmaM&As
60 Exits $37 $200 4.4x $578 12.5x 4.2
1
2
9 11
27
32
28
1
≥ Phase IDevelopment StageCE Mark OnlyFDA-Approved < Phase I
Device M&A continues the trend of early-stage PMA/De Novo exits
and commercial-stage 510(k) exits.
The median upfront deal value of 510(k) companies has increased
and the total deal value has more than doubled from 2015 – 2016
to 2017 – 1H 2018. This has resulted in higher deal value
multiples, with upfront multiples increasing from 2.2x to 3.5x.
Source:PitchBook, press releases and SVB proprietary data.
28. 2
7 5
2
4
4
11
5 4
5
0-1.0x 1.1-2.0x 2.1-4.0x 4.1x-7.0x 7.1-10.0x >10.1x
IPO M&A
Despite experiencing a large 1H 2018 bump in M&A activity and with
immense private capital invested, Dx/Tools M&A deals were smaller
with long times to exit.
Many high-value companies remain private. Of 28 companies with
$150M post-money valuations since 2015, only 3 have exited:
Assurex, Astute and Natera.
Tech companies continue to expand into healthcare through Dx/Tools
investments: Google, Fitbit, Microsoft and Nikon were new corporate
investors in 1H 2018 deals. Looking ahead, tech acquisitions of Dx
Analytics companies are likely in the next two years as tech
companies expand their healthcare footprint and move from
investment to acquisition.
4
6
5
1
3
10
8
5
7
2013
2014
2015
2016
2017
1H 2018
IPO M&A
$-
$0.5
$1.0
$1.5
$2.0
$2.5
$3.0
2013 2014 2015 2016 2017 1H 2018
MeanYearstoIPO 10.9 6.5 7.7 N/A N/A 4.1
Mean Years to M&A 9.1 10.3 7.4 6.4 2.6 4.7
Trends in Healthcare Investments and Exits Mid-Year 2018 28
Dx/Tools M&A Is Up but Values Decline
VC-backed Dx/Tools Exits & IPOs, 2013 – 1H 2018
IPO/Exit Multiples*
2013 – 1H 2018
$1.0B
$1.4B $1.5B
No
Exits
Source:PitchBook, press releases and SVB proprietary data.
*Exit multiple calculated as upfront deal value divided by private invested capital.
Dx Tests are yes/no tests. Dx Analytics provide more information for diagnosis/treatment. R&D Tools advance researchers’ capabilities.
MedianUpfront($M) 350 133 164 225 N/A 105
Median Total Deal ($M) 450 239 164 325 N/A 130
Median Years to Exit 8.2 6.0 3.6 8.5 N/A 8.1
$1.6B
Exit Values by Year
$ BILLIONS
$2.8B
# of Exits by Year
R&D Tools
Dx Analytics
Dx Tests
29. Second Half of 2018 Outlook
Trends in Healthcare Investments and Exits Mid-Year 2018 29
• Wepredictfull-year2018U.S. healthcareventurefundraisingwillreach$9 billion,closelymatchingtherecord
$9.1billionsetin 2017.
• Whilethepaceofbiopharmainvestmentsmay slowin 2H2018,continuinglargeroundsizes likelywillpropel
theannualinvestmenttotaltoa recordhigh.
• BiopharmaM&Ais likelytoreachbetween11 and 13 deals fortheyear. Mostcompanieswillpushtothepublic
marketstoseekhigher-valueIPOs. Weexpectbetween40and 45IPOs for2018, absentunexpectedmarket
fluctuations.
• SeriesCand D dealswilldriveinvestmentin thedevicesector;however,SeriesD valuationresetscoulddilute
early-stageinvestors.
• DeviceM&Aactivity shouldpickup,withquick PMA/DeNovoexitsand improvingmultiplesfor510(k) exits.
WeexpectanotherthreeIPOs in 2H2018,whichwouldbedoublethe2017number.
• Dx/Toolsinvestmentwillfallshortofrecordyear 2017.Investmentin 2H2018willcontinuetofocusonR&D
Toolscompanies.
• Thefieldofsyntheticbiologywillcontinuetogrowas pioneeringcompaniesmakehardwareand biochemical
advancesin DNA/RNAsynthesis.
• HighlyvaluedR&DToolsand liquid biopsycompaniesmay testthepublicmarketsin theU.S. orHongKong,
and weexpectadditional DxTests M&Aactivity.
30. Trends in Healthcare Investments and Exits Mid-Year 2018 30
Glossary
Big Exits
Big Exits defined as a private, venture-backed merger and acquisition
in which the upfront payment is $75 million or more for biopharma
deals and $50 million or more for device and Dx/Tools deals.
Initial Public Offering
IPO defined as a venture-backed company raising IPO proceeds of $25
million or more.
Deal Descriptions
Structured Deal defined as a pay-for-performance acquisition where
some of the deal value is paid upfront when the deal closes, but also
contains additional value based on milestones that must be achieved.
All-in Deal defined as an acquisition where the full deal value is paid
on deal close.
Upfront Payments defined as initial proceeds from an acquisition paid
upon the close of a structured deal; it does not include milestones.
Milestones to be Earned defined as proceeds from an acquisition that
are paid once predetermined milestones are met.
Total Deal Value defined as the full value of the acquisition, including
any milestones to be earned.
Time to Exit defined as the time from the close of a company’s first
institutional round of financing to the exit.
Corporate Investor
Corporate Investor defined as both corporate venture and parent
company investment into venture-backed companies
Regulatory
Non-approved defined as a device company that has no regulatory approval
for its product.
CE Mark Only defined as a device company that has CE Mark approval but
has not received FDA approval. CE Mark is a European Union designation
that is typically less difficult to obtain than FDA approval, and the approval
process often has a faster timeline.
U.S. Commercial defined as a device company that has received FDA
approval of its product and usually is in commercial stage.
Series A
Series A defined as all first-round institutional or corporate venture
investment, and all first-round investments equal to or greater than $2M
regardless of investor.
Indication Definitions
Neurology (neuro) defined as CNS, pain and psychology companies.
Non-Invasive Monitoring defined as medical data collection through sensors
and other technology.
Dx Tests defined as proprietary Yes/No diagnostic tests.
Dx Analytics defined as actionable data analytics to help determine/direct
treatment.
R&D Tools defined as research equipment/services for biopharma and
academia.
Top 15 Crossover Investor
Top 15 Crossover Investor defined as public-minded investor who
strategically invests in private companies. Top 15 list includes: Cormorant
Asset Management, Deerfield Management, EcoR1 Capital, Fidelity
Investments, Foresite Capital Management, Jennison Associates, Partner
Fund Management, Perceptive Advisors, RA Capital Management, Redmile
Group, Rock Springs Capital, Sectoral Asset Management, Viking Global
Investors, Wellington Management and Woodford Investment Management.
31. JonathanNorris
ManagingDirector
SiliconValleyBank
jnorris@svb.com
@jonnysvb
RitishPatnaik
HealthcareConsultant
rp2616@stanford.edu
AndrewOlson
SeniorManager
SVBStrategicAdvisory
aolson@svb.com
BillSideris
SeniorAssociate
SVBStrategicAdvisory
bsideris@svb.com
About the Authors
Trends in Healthcare Investments and Exits Mid-Year 2018 31
AsaManagingDirector,JonathanNorrisspearheadsstrategicrelationshipswithmanyhealthcareventurecapitalfirms.In
addition,hehelpsSVBCapitalthroughsourcingandadvisingonlimitedpartnershipallocationsanddirectinvestments.
Jonathanspeaksatmajorinvestorandindustryconferencesandauthorswidelycitedanalysesofhealthcareventurecapital
trends.Hehas17+yearsofbankingexperienceworkingwithhealthcarecompaniesandventurecapitalfirms.Jonathanearned
aB.S.inBusinessAdministration fromtheUniversityofCalifornia,Riverside,andaJ.D.fromSantaClaraUniversity.
AsaHealthcareConsultant,RitishPatnaikhelpeddevelopSVB’sDx/ToolsandSyntheticBiologyclassificationschemes.Healso
helpedanalyzethedatasets,generatenewslidesandputtogethertakeaways forinvestmenttrendspresentedinthisreport.
Ritish ispursuinga Ph.D. inBioengineeringandM.S. inManagementScienceandEngineeringat StanfordUniversitywherehe
is using bioinformatics and magnetics to create a liver cancer liquid biopsy test. He is a co-founder in Luso Labs, a startup that
bringsaffordablecervicalcancerscreeningworldwide.Ritish earnedaB.S.inBiomedicalEngineeringatColumbiaUniversity.
AndrewOlson is part of SVB’s strategicadvisory groupwherehe partners with both early-stageand larger biotech
companiesto helpthem navigatethe strategicinvestingand M&A landscape.
Beforejoining SVB, Andrewwas a managementconsultantat ZS Associates,wherehe focusedon forecasting,pipeline
strategyand market researchfor pharmaceuticaland biotechcompanies.He holds a B.A. in Chemistryfrom Carleton
Collegein Northfield,Minnesota,and a Ph.D. in Chemistryfromthe Universityof California, Berkeley.
As part of SVB’s strategic advisorygroup,Bill Sideris helpsclientsrefine and executetheir strategicinvestingand
M&A strategyas theycreatethe next generationof medicaltechnologies.
Prior to joining SVB,Bill worked as an R&D engineerat AbbottLaboratoriesfocusedon medicaloptics.Bill also co-
foundedCardian Inc.,a private medicaldevicecompanydevelopinga clinicalstage cardiovascular technologyfor
stroke prevention.Bill completedhis PDEng at the TechnicalUniversityof Delft in BioproductDesignand holds both a
B.S. and M.S. in BiomedicalEngineeringfrom the Universityof Houston.